[HTML][HTML] Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem, C Couteaux, V Olié… - The Lancet Regional …, 2023 - thelancet.com
Summary Background Ending Zero-COVID is challenging, particularly when vaccine
coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by …

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem… - The Lancet …, 2022 - sorbonne-paris-nord.hal.science
Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering
Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low …

[HTML][HTML] Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem, C Couteaux, V Olié… - The Lancet Regional …, 2023 - ncbi.nlm.nih.gov
Background Ending Zero-COVID is challenging, particularly when vaccine coverage is low.
Considering Wallis and Futuna, a French Zero-COVID territory affected by reluctance to …

[HTML][HTML] Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem, C Couteaux, V Olié… - The Lancet Regional …, 2023 - thelancet.com
Summary Background Ending Zero-COVID is challenging, particularly when vaccine
coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by …

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem, C Couteaux, V Olié… - The Lancet Regional …, 2022 - hal.science
Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering
Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low …

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem, C Couteaux… - The Lancet Regional …, 2022 - pasteur.hal.science
Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering
Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low …

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem, C Couteaux… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Ending Zero-COVID is challenging, particularly when vaccine coverage is low.
Considering Wallis and Futuna, a French Zero-COVID territory affected by reluctance to …

[HTML][HTML] Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem, C Couteaux, V Olié… - The Lancet Regional …, 2023 - Elsevier
Summary Background Ending Zero-COVID is challenging, particularly when vaccine
coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by …

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem, C Couteaux… - The Lancet …, 2022 - ut3-toulouseinp.hal.science
Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering
Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low …

[PDF][PDF] Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

A Brault, C Tran-Kiem, C Couteaux, V Olié, J Paireau… - 2022 - scienceopen.com
Summary Background Ending Zero-COVID is challenging, particularly when vaccine
coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by …